Comparison of the metabolism and toxicity of dapsone in rat, mouse and man
- PMID: 9353403
Comparison of the metabolism and toxicity of dapsone in rat, mouse and man
Abstract
The metabolism and toxicity of dapsone was compared in vitro and in vivo in rat, mouse and man. Metabolism was assessed by high-pressure liquid chromatography-mass spectrometry and methemoglobin formation has been used as a toxic endpoint. The greatest toxicity in vitro was seen in microsomes prepared from male Wistar rats (36.6 +/- 1.5% methemoglobin), although toxicity was also seen in microsomes from the female rat (8.2 +/- 1.3%), male CD1 (4.2 +/- 1.6%) and human (10. 9 +/- 1.1%). The rank order of toxicity agreed with the formation of the hydroxylamine metabolite in vitro. All microsomes were also capable of catalyzing the reverse reaction, i.e., reduction of the hydroxylamine to dapsone. However, in vivo administration of dapsone resulted in significant (P < 0.05) methemoglobinemia only in male rats and humans. This species difference in the susceptibility to dapsone toxicity could not be attributed solely to the sensitivity of the target erythrocytes, because the order of sensitivity to dapsone hydroxylamine was human > mouse > rat. Analysis of bile and urine revealed the formation of dapsone hydroxylamine and its glucuronide in male rats and humans, but not in female rats or mice. This species difference in the metabolism and toxicity of dapsone has important implications in the safety evaluation of related compounds for man.
Similar articles
-
Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites.J Pharmacol Exp Ther. 1973 Oct;187(1):138-51. J Pharmacol Exp Ther. 1973. PMID: 4583459 Clinical Trial. No abstract available.
-
Dapsone-induced hematologic toxicity: comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood.Toxicol Appl Pharmacol. 1994 Dec;129(2):309-16. doi: 10.1006/taap.1994.1255. Toxicol Appl Pharmacol. 1994. PMID: 7992320
-
Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes.Drug Metab Dispos. 1994 Jan-Feb;22(1):161-4. Drug Metab Dispos. 1994. PMID: 8149877
-
NTP Technical Report on the metabolism, toxicity and predicted carcinogenicity of diazoaminobenzene (CAS No. 136-35-6).Toxic Rep Ser. 2002 Sep;(73):1-23, A1-C6. Toxic Rep Ser. 2002. PMID: 12370695 Review.
-
Dapsone toxicity: some current perspectives.Gen Pharmacol. 1995 Nov;26(7):1461-7. doi: 10.1016/0306-3623(95)00029-1. Gen Pharmacol. 1995. PMID: 8690232 Review.
Cited by
-
Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions.Pharmaceutics. 2019 Nov 13;11(11):607. doi: 10.3390/pharmaceutics11110607. Pharmaceutics. 2019. PMID: 31766282 Free PMC article.
-
Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.PLoS One. 2014 Jan 22;9(1):e85712. doi: 10.1371/journal.pone.0085712. eCollection 2014. PLoS One. 2014. PMID: 24465659 Free PMC article.
-
Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.Eur J Clin Pharmacol. 2009 Oct;65(10):977-87. doi: 10.1007/s00228-009-0672-1. Epub 2009 Jun 11. Eur J Clin Pharmacol. 2009. PMID: 19517101 Clinical Trial.
-
Toxicology laboratory analysis and human exposure to p-chloroaniline.Clin Toxicol (Phila). 2009 Feb;47(2):132-6. doi: 10.1080/15563650801971390. Clin Toxicol (Phila). 2009. PMID: 18608262 Free PMC article.
-
Dapsone in dermatology and beyond.Arch Dermatol Res. 2014 Mar;306(2):103-24. doi: 10.1007/s00403-013-1409-7. Epub 2013 Dec 6. Arch Dermatol Res. 2014. PMID: 24310318 Free PMC article. Review.